Abstract
Most patients with Crohn's disease will require surgery during the course of their disease. However, surgery is not curative and post-operative recurrence is quite inexorable. One year after resection up to 80% of patients have new lesions at the neo-terminal ileum and after 10 years approximately 50% of patients will experience recurrence of symptoms and 35% will need further surgery. Prevention of post-operative recurrence has, therefore, a central role in the management of Crohn's Disease. Several drugs have been evaluated to decrease the risk of both endoscopic and clinical recurrence but the overall results are largely not impressive. Among the different drugs evaluated, mesalazine, antibiotics (metronidazole and ornidazole), thiopurines and anti-TNFα antibodies have been shown to be effective whereas budesonide, probiotics and interleukin 10 are not effective. This review focuses on the actual evidence on the prevention of postoperative recurrence: randomised controlled trials and meta-analyses are critically reviewed and discussed with particular attention to the methodological aspects.
Keywords: Crohn's disease, post-operative recurrence, mesalazine, thiopurines, biologic therapies, antibiotics, probiotics, budesonide
Reviews on Recent Clinical Trials
Title:Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease
Volume: 7 Issue: 4
Author(s): Claudio Papi, Federica Fasci Spurio, Giovanna Margagnoni and Annalisa Aratari
Affiliation:
Keywords: Crohn's disease, post-operative recurrence, mesalazine, thiopurines, biologic therapies, antibiotics, probiotics, budesonide
Abstract: Most patients with Crohn's disease will require surgery during the course of their disease. However, surgery is not curative and post-operative recurrence is quite inexorable. One year after resection up to 80% of patients have new lesions at the neo-terminal ileum and after 10 years approximately 50% of patients will experience recurrence of symptoms and 35% will need further surgery. Prevention of post-operative recurrence has, therefore, a central role in the management of Crohn's Disease. Several drugs have been evaluated to decrease the risk of both endoscopic and clinical recurrence but the overall results are largely not impressive. Among the different drugs evaluated, mesalazine, antibiotics (metronidazole and ornidazole), thiopurines and anti-TNFα antibodies have been shown to be effective whereas budesonide, probiotics and interleukin 10 are not effective. This review focuses on the actual evidence on the prevention of postoperative recurrence: randomised controlled trials and meta-analyses are critically reviewed and discussed with particular attention to the methodological aspects.
Export Options
About this article
Cite this article as:
Papi Claudio, Fasci Spurio Federica, Margagnoni Giovanna and Aratari Annalisa, Randomized Controlled Trials in Prevention of PostSurgical Recurrence in Crohn’s Disease, Reviews on Recent Clinical Trials 2012; 7 (4) . https://dx.doi.org/10.2174/1574887111207040307
DOI https://dx.doi.org/10.2174/1574887111207040307 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of the RAS in Pancreatic Cancer
Current Cancer Drug Targets Ferroptosis and Hydrogen Sulfide in Cardiovascular Disease
Current Medicinal Chemistry Human Stem Cells and Articular Cartilage Tissue Engineering
Current Pharmaceutical Biotechnology Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Alcoholic Liver Disease: from CYP2E1 to CYP2A5
Current Molecular Pharmacology A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Omega-3 Fatty Acids in the Management of Epilepsy
Current Topics in Medicinal Chemistry Searching for Artemisinin Production Improvement in Plants and Microorganisms
Current Pharmaceutical Biotechnology Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia
Current Neurovascular Research COVID-19 and Renal Diseases: An Update
Current Drug Targets Cystic Fibrosis, Vector-Mediated Gene Therapy, and Relevance of Toll-Like Receptors: A Review of Problems, Progress, and Possibilities
Current Gene Therapy Recent Patents on Topical Application of Honey in Wound and Burn Management
Recent Patents on Inflammation & Allergy Drug Discovery Targeting ADAM17 Sheddase Activity in Cancer
Current Drug Targets Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Current Cancer Therapy Reviews The Dramatic Role of IFN Family in Aberrant Inflammatory Osteolysis
Current Gene Therapy Synthesis, Anti-inflammatory Activities and Mechanisms of 3,5- dihydroxycinnamic Acid Derivatives
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry